Loading…
Based on limited metadata, the FDA issued a warning letter to Broncolin, S.A. de C.V., a drug manufacturer, on December 21, 2020. While the specific violations are not detailed in the available metadata, the warning letter indicates regulatory concerns with the company's drug products or manufacturing practices. The action falls under FDA's drug product oversight authority, though the specific issuing office and detailed violation count are not provided in this summary record.